Published in Physiol Rep on August 01, 2015
Device-based Therapy for Hypertension. Curr Hypertens Rep (2016) 0.82
Chronic cyclic vagus nerve stimulation has beneficial electrophysiological effects on healthy hearts in the absence of autonomic imbalance. Physiol Rep (2016) 0.75
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension (2004) 6.80
The sympathetic control of blood pressure. Nat Rev Neurosci (2006) 6.44
Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest (2007) 5.55
Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens (2005) 4.19
Spatial and temporal organization during cardiac fibrillation. Nature (1998) 4.01
Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation (1998) 3.99
Effect of action potential duration and conduction velocity restitution and their spatial dispersion on alternans and the stability of arrhythmias. J Cardiovasc Electrophysiol (2002) 3.29
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
Mechanisms of discordant alternans and induction of reentry in simulated cardiac tissue. Circulation (2000) 2.73
Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res (1991) 2.41
Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension (2010) 2.38
Circulating angiotensin II and dietary salt: converging signals for neurogenic hypertension. Curr Hypertens Rep (2007) 2.23
Altered connexin expression in human congestive heart failure. J Mol Cell Cardiol (2001) 2.15
Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail (2009) 2.09
Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation (2008) 1.83
Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with healed myocardial infarction. An experimental preparation for sudden cardiac death. Circulation (1984) 1.63
Reflex discharge patterns of cardiac vagal efferent fibres. J Physiol (1972) 1.61
Efferent vagal nerve stimulation protects heart against ischemia-induced arrhythmias by preserving connexin43 protein. Circulation (2005) 1.46
Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol (2002) 1.45
Vagus nerve stimulation protects against ventricular fibrillation independent of muscarinic receptor activation. Cardiovasc Res (2011) 1.31
Cardiac mitochondria and arrhythmias. Cardiovasc Res (2010) 1.29
Effects of vagal stimulation on experimentally induced seizures in rats. Epilepsia (1990) 1.27
Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice. Acta Physiol Scand (2003) 1.26
Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex. Am J Physiol Heart Circ Physiol (2010) 1.24
Protective effect of vagal stimulation on reperfusion arrhythmias in cats. Circ Res (1987) 1.20
Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens (2012) 1.19
Brainstem mechanisms of hypertension: role of the rostral ventrolateral medulla. Curr Hypertens Rep (2003) 1.14
Nitric oxide mediates the vagal protective effect on ventricular fibrillation via effects on action potential duration restitution in the rabbit heart. J Physiol (2007) 1.11
Direct evidence of nitric oxide release from neuronal nitric oxide synthase activation in the left ventricle as a result of cervical vagus nerve stimulation. J Physiol (2009) 1.08
Role of spinal V1a receptors in regulation of arterial pressure during acute and chronic osmotic stress. Am J Physiol Regul Integr Comp Physiol (2010) 1.02
Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial. J Card Fail (2014) 1.01
Spatial distribution of connexin43, the major cardiac gap junction protein, in the developing and adult rat heart. Circ Res (1991) 0.97
Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics. Heart Fail Rev (2000) 0.97
Resistant hypertension: prevalence and evolving concepts. J Clin Hypertens (Greenwich) (2007) 0.95
Slow hyperpolarization in cortical neurons: a possible mechanism behind vagus nerve simulation therapy for refractory epilepsy? Epilepsia (2000) 0.92
The little brain on the heart. Cleve Clin J Med (2007) 0.91
Diastolic dysfunction: a link between hypertension and heart failure. Drugs Today (Barc) (2008) 0.91
Effects of efferent vagal stimulation on atrial and ventricular function. Am J Physiol (1968) 0.90
Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients. Eur J Vasc Endovasc Surg (2006) 0.90
Consequences of the increased autonomic nervous drive in hypertension, heart failure and diabetes. Blood Press Suppl (1998) 0.89
Vagus nerve stimulation initiated late during ischemia, but not reperfusion, exerts cardioprotection via amelioration of cardiac mitochondrial dysfunction. Heart Rhythm (2014) 0.87
Hypertension and arrhythmia: blood pressure control and beyond. Europace (2002) 0.87
Dependence of deoxycorticosterone/salt hypertension in the rat on the activity of adrenergic cardiac nerves. Clin Sci (Lond) (1979) 0.84
Evidence favoring the hypothesis that ventricular arrhythmias have prognostic significance in left ventricular hypertrophy secondary to systemic hypertension. Am J Cardiol (1995) 0.82
The effect of cardiac sympathetic denervation through bilateral stellate ganglionectomy on electrical properties of the heart. Am J Physiol Heart Circ Physiol (2011) 0.82
Baroreflex activation for the treatment of heart failure. Curr Cardiol Rep (2012) 0.81
Prognostic significance of ventricular arrhythmias in the presence of pathological left ventricular hypertrophy. Eur Heart J (1993) 0.79
Effect of beta-adrenergic blockade on dynamic electrical restitution in vivo. Am J Physiol Heart Circ Physiol (2004) 0.78
Intermittent vagal nerve stimulation alters the electrophysiological properties of atrium in the myocardial infarction rat model. Conf Proc IEEE Eng Med Biol Soc (2014) 0.78
Heart rate variability: how to assess effects of mild therapies on autonomic control in small groups of mild and borderline hypertensives? Hypertension (2000) 0.77
Involvement of the autonomic nervous system in diurnal variation of corrected QT intervals in common marmosets. J Pharmacol Sci (2013) 0.76
Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation. Sci Rep (2015) 0.78